FDA Approves Merck's BRAVECTO QUANTUM Annual Flea and Tick Shot for Dogs: A New Era in Canine Protection

Merck Animal Health has received FDA approval for BRAVECTO QUANTUM, a once-yearly injectable product for dogs to treat and prevent flea and tick infestations. The product is expected to be available nationwide by August 2025 and is approved in over 50 countries worldwide. BRAVECTO QUANTUM kills adult fleas and is indicated for the treatment and control of various tick species for 12 months in dogs and puppies 6 months of age and older.

Merck Animal Health, a division of Merck & Co., Inc. (NYSE: MRK), has received U.S. Food and Drug Administration (FDA) approval for Bravecto Quantum, an injectable treatment designed to protect dogs from fleas and ticks with just one dose per year. This product is anticipated to be available in veterinary clinics and hospitals nationwide by August 2025 [1].

Bravecto Quantum, which utilizes a unique, patented composition of fluralaner, offers year-long flea and tick protection with a single injection. The treatment is indicated for the treatment and prevention of flea infestations and the treatment and control of various tick species for 12 months in dogs and puppies 6 months of age and older. It also provides protection against the lone star tick for 8 months [2].

The approval of Bravecto Quantum marks a significant milestone for Merck Animal Health, which has been recognized for its leadership in long-acting preventative parasiticides. The product has already gained approval in over 50 countries, including Australia, New Zealand, and the European Union [2]. Merck Animal Health expects this product to simplify flea and tick control for both pet owners and veterinarians, promoting better compliance and reducing the risk of diseases transmitted by these parasites [2].

Frank Guerino, Ph.D., associate vice president of Global Pharmaceutical Development at Merck Animal Health, stated, "Though people often think of flea and tick season during the summer months, studies have shown that while fleas and ticks are most active from early spring through the fall, they can be a threat year-round, especially knowing it only takes a few warm days for ticks to become active. With Bravecto Quantum, a single dose provides year-long, continuous protection, simplifying care for both pet owners and veterinarians, and promoting compliance" [2].

Bravecto Quantum exemplifies Merck Animal Health's commitment to groundbreaking science and has been recognized as a winner of the 2024 Edison Awards and the 2024 S&P Global Awards for Best New Companion Animal Product. The product is only available through licensed veterinarians and is not effective against lone star ticks beyond 8 months of dosing [2].

References:
[1] https://seekingalpha.com/news/4466644-merck-animal-health-gets-fda-nod-for-bravecto-quantum
[2] https://www.morningstar.com/news/business-wire/20250707315992/fda-approves-bravecto-quantum-fluralaner-for-extended-release-injectable-suspension-from-merck-animal-health